11 research outputs found
The pseudogap: friend or foe of high Tc?
Although nineteen years have passed since the discovery of high temperature
superconductivity, there is still no consensus on its physical origin. This is
in large part because of a lack of understanding of the state of matter out of
which the superconductivity arises. In optimally and underdoped materials, this
state exhibits a pseudogap at temperatures large compared to the
superconducting transition temperature. Although discovered only three years
after the pioneering work of Bednorz and Muller, the physical origin of this
pseudogap behavior and whether it constitutes a distinct phase of matter is
still shrouded in mystery. In the summer of 2004, a band of physicists gathered
for five weeks at the Aspen Center for Physics to discuss the pseudogap. In
this perspective, we would like to summarize some of the results presented
there and discuss its importance in the context of strongly correlated electron
systems.Comment: expanded version, 20 pages, 11 figures, to be published, Advances in
Physic
Pair Breaking, Pseudogap, and Superconducting Tc of Hole-Doped Cuprates: Interrelations and Implications
Structural and electrical properties of c-axis oriented Y-Ca-Ba-Cu-Zn-O thin films grown by pulsed laser deposition
Structural and electrical properties of c-axis oriented Y-Ca-Ba-Cu-Zn-O thin films grown by pulsed laser deposition
Unusual Enhancement of Normal and Superconducting State Properties of (100-x)YBa2Cu3O7-δ + xNi (x = 1, 2.5, 5, 7.5, 10, and 15 wt%) Composites with Low Level of Ni Additives
Superconducting parameter determination for (Co0.5Zn0.5Fe2O4) x /Cu0.5Tl0.5-1223 composite
Geostatistical lithofacies modeling of the upper sandstone member/Zubair formation in south Rumaila oil field, Iraq
The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon
Toll-like receptor 9 (TLR9) agonists are being developed for treatment of colorectal and other cancers, yet the impact of these drugs on human intestines remains unknown. This, together with the fact that there are additional potential indications for TLR9 agonist therapy (e.g., autoimmune and infectious diseases), led us to investigate the impact of MGN1703 (Lefitolimod) on intestinal homeostasis and viral persistence in HIV-positive individuals. Colonic sigmoid biopsies were collected (baseline and week four) from 11 HIV+ individuals on suppressive antiretroviral therapy, who received MGN1703 (60 mg s.c.) twice weekly for 4 weeks in a single-arm, phase 1b/2a study. Within sigmoid mucosa, global transcriptomic analyses revealed 248 modulated genes (false discovery rate<0.05) including many type I interferon (IFN)-stimulated genes. MGN1703 increased the frequencies of cells exhibiting MX1 (P=0.001) and ISG15 (P=0.014) protein expression. No changes were observed in neutrophil infiltration (myeloperoxidase; P=0.97). No systematic effect on fecal microbiota structure was observed (analysis of similarity Global R=-0.105; P=0.929). TLR9 expression at baseline was inversely proportional to the change in integrated HIV DNA during MGN1703 treatment (P=0.020). In conclusion, MGN1703 induced a potent type I IFN response, without a concomitant general inflammatory response, in the intestines